Close menu




November 11th, 2021 | 14:42 CET

PayPal, wallstreet:online, Palantir - Flying too high

  • Investments
Photo credits: pixabay.com

The reporting season for the third quarter is coming to an end. Currently, mainly the technology companies are reporting on the completed quarter. Although many of them achieve their internal targets and analysts' forecasts, market participants react with share price losses due to the excessive valuations that have been in place for months. Due to the relatively weaker second quarter, most online brokers are already at the end of their correction phase and could start a new wave upwards as the stock market continues to boom.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: PAYPAL HDGS INC.DL-_0001 | US70450Y1038 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:


    wallstreet:online - The best of everything

    wallstreet:online AG's Smartbroker offers the best of all worlds. Smartbroker is a hybrid broker, firstly because the fees are close to those of the neobrokers, and secondly, because the Berliners offer more than one trading venue, unlike the highly acclaimed newcomers to the industry. In addition, the advantage lies in the average securities account volume of a customer. While an investor at Smartbroker has an average of more than EUR 33,000, the new brokers lag far behind with customer deposits in the range between EUR 3,000 and EUR 5,000. Moreover, wallstreet:online has other advantages that have grown since the early 2000s.

    With portals such as wallstreet-online.de, boersenNews.de, FinanzNachrichten.de and ARIVA.de, which have all grown over the years, more than 500,000 registered users are ready to trade via the capital city broker in the future. CEO Matthias Hach wants to further accelerate closer integration in the future and thereby increase trading activity. In addition, a new smartphone app will be expanded in the first quarter of 2022 to offer competition to neobrokers. In addition to optimizing the Smartbroker platform, the Berlin-based company plans to expand its existing KWG license. The aim is to expand the financial services business further and extend the license from securities trading bank to securities institution for this purpose.

    The Berlin-based Company's share price has suffered somewhat in recent weeks due to the general market correction. After highs in June at just under EUR 30.00, the pier briefly fell below the EUR 20.00 mark. In the long term, wallstreet:online has a clear, unique selling proposition due to the combination of community and broker.

    Palantir - Punished again

    It seems to have become a habit that the data analysis specialist is punished after announcing their figures. This time, too, a slide in the Palantir share price of around 10% followed. That brings the price close to the striking resistance area at USD 24.00. Through a downward breakout, the value could then rejoin its sideways range in a range between USD 20 and USD 24, which it had only recently left to the upside.

    The figures of the Big Data company were definitely in the range or slightly above analysts' expectations. In particular, the revenue growth of 36% to USD 392.15 million promised by CEO Alex Karp was still maintained. Compared to the previous quarter, this even meant an increase of almost 50%. Compared to the same quarter of the previous year, the operating margin also improved from 25% to 30%. Thus, the operating result amounted to EUR 91.94 million. Net income improved to USD -102.14 million compared to USD -853.32 million in the same period of 2020, resulting in earnings per share of USD -0.05.

    For the current year 2021, Palantir expects growth of around 40% to approximately USD 1.725 billion. Thus, it looks like the CEO's promise continues to hold. After the numbers, star fund manager Cathie Woods spoke up. The self-confessed fan of the data analytics company is once again buying the dip. According to reports, asset management firm Ark Invest bought 1.48 million shares worth an estimated USD 35.98 million on Tuesday.

    PayPal - Down after the numbers

    A similar pattern to Palantir's also occurred at payment services provider PayPal after it announced its third-quarter figures. Despite solid figures, the paper plunged about 5%. Like Palantir, whose market capitalization is an enormous USD 48.62 billion, PayPal's stock is seen as more than ambitiously valued at USD 241.35 billion. From a purely technical point of view, there is no investment at USD 204.35 at the moment. Instead, the share runs the risk of falling back into the area around USD 175.

    Looking at the figures, sales increased, but the pace slowed considerably after the boom during the Corona lockdowns. In the third quarter, revenues climbed 13% YOY to USD 6.2 billion. Profit rose 6% to USD 1.1 billion. At USD 1.11 per share, the Company beat analysts' consensus estimates of USD 1.07. On the outlook, however, PayPal had to cut its guidance targets. News that a cooperation between Amazon and Venmo is being sought provided for an after-market increase. Thus, the e-commerce giant is to allow payments via the PayPal subsidiary from next year.


    Despite meeting forecasts, the figures of the technology companies Palantir and PayPal were poorly received due to the high valuation; the shares corrected strongly. A shakeout also has the share of wallstreet:online behind it. At the current level, however, the Company is interesting because of its USP.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read